Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06737835
Starting soon Observational

Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma

NCT06737835 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-01-01
Last updated
2024-12-17

Condition(s) studied

Lymphoma

Investigational drug(s) / intervention(s)

18 FDG

18 FDG: 18 flurodeoxy glucose PET/CT

Study summary

1. To assess staging accuracy of F-18 FDG PET/CT in lymphoma
2. Determine the role of F-18 FDG PET/CT in monitoring treatment response and detecting relapse or residual disease in lymphoma
3. To evaluate FDG uptake correlation with histopathological subtypes and immunophenotypes as a prognostic factor.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age: Patient must be older than 18 years. * Confirmed Diagnosis of Lymphoma: Patient must have a confirmed diagnosis of lymphoma based on histopathology and immunophenotyping. Exclusion Criteria: * Patients with Known concomitant malignancy. * Pregnancy: Pregnant women due to the potential risks associated with radiation exposure from the PET/CT scan. * Severe Renal or Hepatic Impairment: Patients with significant renal or hepatic dysfunction that could affect FDG metabolism or excretion. * Uncontrolled Diabetes: Patients with uncontrolled diabetes (blood glucose \>200 mg/dL), as it can affect FDG uptake and PET/CT results.

Primary outcome measure(s)

  • primary — 3 years
    Treatment Response Using Deauville Score for FDG Uptake Evaluation: Evaluate FDG uptake using the 5-point scale: 1. No uptake above background 2. Uptake ≤ mediastinum 3. Uptake \> mediastinum but ≤ liver 4. Moderately increased compared to liver 5. Markedly increased compared to liver X: New uptake, unlikely related to lymphoma

Trial sites (1)

FacilityCityRegionStatus
Nuclear medicine- Assiut University Hospital Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon

Other trials for the same condition

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease Active, not recruiting
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma Recruiting
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06737835 on ClinicalTrials.gov ↗ ← All trials in Egypt